Literature DB >> 32770086

Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.

Onima Chowdhury1, Jennifer O'Sullivan1, Nikolaos Barkas1, Guanlin Wang1, Gemma Buck1, Angela Hamblin1, Ayalew Tefferi2, Haifa K Al-Ali3, Giovanni Barosi4, Timothy Devos5, Heinz Gisslinger6, Qian Jiang7, Jean-Jacques Kiladjian8, Ruben Mesa9, Francesco Passamonti10, Vincent Ribrag11, Gary Schiller12, Alessandro M Vannucchi13, Daobin Zhou14, Mary Frances McMullin15, Jianhua Zhong16, Robert Peter Gale17, Adam J Mead18.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32770086      PMCID: PMC7610567          DOI: 10.1038/s41375-020-0979-6

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

Review 1.  Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Authors:  A M Vannucchi; E Antonioli; P Guglielmelli; A Pardanani; A Tefferi
Journal:  Leukemia       Date:  2008-05-22       Impact factor: 11.528

2.  Targeted deep sequencing in primary myelofibrosis.

Authors:  Ayalew Tefferi; Terra L Lasho; Christy M Finke; Yoseph Elala; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Blood Adv       Date:  2016-11-30

3.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

4.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

5.  High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.

Authors:  Anna Jonasova; Radka Bokorova; Jaroslav Polak; Martin Vostry; Arnost Kostecka; Hana Hajkova; Radana Neuwirtova; Magda Siskova; Dana Sponerova; Jaroslav Cermak; Dana Mikulenkova; Libor Cervinek; Jana Brezinova; Kyra Michalova; Ota Fuchs
Journal:  Eur J Haematol       Date:  2014-10-31       Impact factor: 2.997

6.  Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

Authors:  Fabio P S Santos; Bartlomiej Getta; Lucia Masarova; Christopher Famulare; Jessica Schulman; Tarcila S Datoguia; Renato D Puga; Raquel de Melo Alves Paiva; Maria E Arcila; Nelson Hamerschlak; Hagop M Kantarjian; Ross L Levine; Paulo Vidal Campregher; Raajit K Rampal; Srdan Verstovsek
Journal:  Leukemia       Date:  2019-10-18       Impact factor: 11.528

7.  GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.

Authors:  Ayalew Tefferi; Paola Guglielmelli; Maura Nicolosi; Francesco Mannelli; Mythri Mudireddy; Niccolo Bartalucci; Christy M Finke; Terra L Lasho; Curtis A Hanson; Rhett P Ketterling; Kebede H Begna; Animesh Pardanani; Alessandro M Vannucchi
Journal:  Leukemia       Date:  2018-03-23       Impact factor: 11.528

8.  U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions.

Authors:  Ayalew Tefferi; Christy M Finke; Terra L Lasho; Curtis A Hanson; Rhett P Ketterling; Naseema Gangat; Animesh Pardanani
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

9.  A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.

Authors:  A Tefferi; H K Al-Ali; G Barosi; T Devos; H Gisslinger; Q Jiang; J-J Kiladjian; R Mesa; F Passamonti; M F McMullin; V Ribrag; G Schiller; A M Vannucchi; D Zhou; D Reiser; J Zhong; R P Gale
Journal:  Leukemia       Date:  2017-05       Impact factor: 11.528

10.  Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments.

Authors:  Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2017-12-15       Impact factor: 11.037

View more
  1 in total

Review 1.  Genetic Background of Polycythemia Vera.

Authors:  Mathilde Regimbeau; Romain Mary; François Hermetet; François Girodon
Journal:  Genes (Basel)       Date:  2022-04-02       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.